Skip to Content

Vabomere Approval History

  • FDA approved: Yes (First approved August 29th, 2017)
  • Brand name: Vabomere
  • Generic name: meropenem and vaborbactam
  • Dosage form: Injection
  • Previous name: Carbavance
  • Company: The Medicines Company
  • Treatment for: Urinary Tract Infection

Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).

Development History and FDA Approval Process for Vabomere

DateArticle
Aug 29, 2017Approval FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections
Feb 21, 2017The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide